ERBB2 and breast carcinoma: Interestingly, ERRα promoted the survival of epidermal growth factor receptor 2 (HER2)-positive breast cancer cells resistant to lapatinib, suggesting that ERRα inhibition may be an effective adjuvant therapy in HER2-positive breast cancer with poor outcome[20].